In detail, tumor-bearing mice treated with D2-asd carrying RGD4C-ES, RGD10-ES, or PSMA-ES survived for over 30 days, followed by mice treated with ST/ES for 23 days, whereas the median survival time of ST/3342- and PBS-treated mice was 20 and 17 days, respectively (Figure 5D). Here, FOLH1 is linked to neoplasm.